The National Agency for Food and Drugs Administration and Control has warned Nigerians against purchasing a suspected counterfeit Augmentin 625mg Tabs that is being circulated in the country.
NAFDAC raised the alarm in a statement titled ‘NAFDAC Alert And Sensitization Of The Public On Suspected Falsified Augmentin 625mg’.
In the statement posted on the agency’s website, NAFDAC said the product failed short of the labeling requirements.
According to the statement, the batch number of the falsified drug is 562626 while the NAFDAC registration number is 04-1928.
The agency also disclosed that the fake drug was manufactured in April 2021 and would expire on April 2024.
The statement reads, “The product failed short of the labeling requirements. No inscription “manufactured by” is written on the label -only the address.
“Manufacturing and Expiry dates do not meet the acceptable format. No MAS scratch number for verification.
READ ALSO: Police launch manhunt to arrest ex-convict
“The logo “gsk” is not properly positioned as on the original. The listed information indicates the product is falsified and counterfeited.
“In view of the above, NAFDAC has notified all its formations in the zones and 36 states of the federation including the FCT to carry out surveillance and mop up the falsified Augmentin tablets.”
It added, “Please note that the genuine Augmentin 625mg has legible product labeling information including date markings – expiration and manufactured dates, batch number and NAFDAC registration number.
“NAFDAC advise to wholesalers, distributors, and pharmacies is that medicines should be obtained from authorized/licensed suppliers, increased vigilance is hereby encouraged within the supply chain to avoid infiltration of the falsified product. The products’ authenticity, physical condition and labels should be carefully checked.
“NAFDAC implores healthcare providers to ensure vigilance to prevent the administration of falsified products to unsuspecting patients. Members of the public in possession of the above suspected counterfeit product are advised to discontinue sale or use and submit stock to the nearest NAFDAC office.
“Healthcare providers and the public should notify the nearest NAFDAC office of any information concerning the distribution, sale, and use of the falsified version of the Augmentin product. Report any suspicion of adverse drug reaction and substandard and falsified medicines to NAFDAC on 0800-162-3322 or email: sf.alert@nafdac.gov.ng.”